Furthermore, MRE11 has been shown to function as a barrier to tumourigenesis [109, 110], and inherited heterozygous mutations in MRE11, NBS1 or RAD50 are associated with a low-intermediate penetrance risk of breast cancer [111–113]. Here, MRE11 is linked to breast carcinoma.